Dignitana AB (http://www.dignitana.se/), world leader in scalp cooling innovation, announces today that the company has signed a new distributor, AMI Medical Technologies (http://www.ami.co.il/) in Israel, as well as a contract for the sale of the first DigniCap Delta devices in the country.  On the heels of regulatory approval in September, Dignitana has also now sold the first DigniCap Delta units in Australia through longtime distribution partner Aurora BioScience (http://aurorabioscience.com.au/). AMI Medical  Technologies is a leading distributor of medical devices and innovative technology in Israel with over 30 years of experience introducing and establishing the widespread use of breakthrough medical technology. "This is a meaningful development in our commitment to make DigniCap widely available worldwide," said William Cronin, CEO of Dignitana AB. "AMI Medical Technologies has extensive experience in acclimating medical technologies to local and international health systems. This is a significant advantage as we introduce this life-changing product to Israel. "We are proud to work with Dignitana to bring scalp cooling therapeutics to Israel," said Tali  Schachter , CEO of AMI Medical  Technologies. "This is an important opportunity to apply our collective expertise to make a meaningful impact on the quality of life of individuals who are affected by cancer and the devastating side effects of treatment." The DigniCap Scalp Cooling System has FDA clearance and CE marking to minimize hair loss in chemotherapy patients diagnosed with solid tumor cancers. Recently permission to sell DigniCap in Israel was granted after a registration and review by The Israel Ministry of Health Medical Device division (AMAR).  In September Dignitana received regulatory clearance from the Therapeutic Goods Administration (TGA)  to sell DigniCap Delta in Australia. “In Australia scalp cooling is already a standard of care for cancer patients, and it continues to be a very important market for us,” Cronin added. “DigniCap Delta allows our partner sites to offer this valuable therapy option to more patients and much more efficiently.” The integration of scalp cooling into comprehensive cancer care in Israel will play an especially important role in improving well-being among the country’s at-risk patient populations. In Ashkenazi Jewish women (https://ww5.komen.org/BreastCancer/AshkenaziJewishHeritage.html) in particular, there is a high occurrence of BRCA1 and BRCA2 gene mutations, the former of which is associated with a 65 percent chance of developing breast cancer.